Lucence declares the opening of molecular diagnostics lab in Singapore
Category: #health  By Pankaj Singh  Date: 2019-02-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lucence declares the opening of molecular diagnostics lab in Singapore

Lucence Diagnostics has reportedly made it to the headlines for having announced the opening of its new headquarters & molecular diagnostics laboratory in Singapore. As per sources familiar with the matter, the new facility spanning 10,000 square feet will help the firm penetrate into newer regional markets and meet the rising demand for its clinical services, in addition to upscaling its R&D operations.

Incidentally, the company has already expanded its business operations across San Francisco & Hong Kong and now plans to tap the Singapore market.

Renowned for inventing blood tests for rapid as well as non-invasive cancer detection, Lucence’s blood tests are officially available in around right countries, inclusive of Singapore, India, Philippines, Hong Kong, Malaysia, Thailand, Myanmar, and Vietnam. According to a press release by Lucence Diagnostics, alongside the opening of its new molecular diagnostics facility, the company has also launched its flagship blood test LiquidHALLMARK®, capable of detecting around 50 genetic mutations, 2 viruses, and 14 types of cancers. The LiquidHALLMARK® is the first blood test of its kind that detects both cancer-causing viruses and genetic mutations with an astounding 99.9% accuracy and delivers an intensive molecular profile of the tumor with just a single blood draw using AmpliMARK™ - the firm’s proprietary amplicon-based sequencing technology.

Dr. Tan Min-Han, Founder & CEO, Lucence Diagnostics, was reportedly quoted stating that the expanded molecular diagnostics laboratory is the first step ahead for the company to fulfill its vision of attaining zero avoidable cancer deaths via early detection and enhanced treatment choices. Min-Han affirmed that the company is indeed thrilled to have played a pivotal role in bettering the lives of thousands of patients across Asia with its portfolio of blood tests for cancer screening and treatment selection.

The opening at Singapore incidentally, was officiated by Dr. Koh Poh Koon, Senior Minister of State, Ministry of Trade & Industry.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...